TY  - JOUR
AU  - Thomas, M
AU  - Ponce-Aix, S
AU  - Navarro, A
AU  - Riera-Knorrenschild, J
AU  - Schmidt, M
AU  - Wiegert, E
AU  - Kapp, K
AU  - Wittig, B
AU  - Mauri, C
AU  - Dómine Gómez, M
AU  - Kollmeier, J
AU  - Sadjadian, P
AU  - Fröhling, K-P
AU  - Huber, R M
AU  - Wolf, M
AU  - IMPULSE study team
PY  - 2018
DO  - 10.1093/annonc/mdy326
UR  - https://hdl.handle.net/10668/26886
T2  - Annals of oncology : official journal of the European Society for Medical Oncology
AB  - The immune surveillance reactivator lefitolimod (MGN1703), a DNA-based TLR9 agonist, might foster innate and adaptive immune response and thus improve immune-mediated control of residual cancer disease. The IMPULSE phase II study evaluated the...
LA  - en
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - Carboplatin
KW  - Cisplatin
KW  - Cohort Studies
KW  - Etoposide
KW  - Follow-Up Studies
KW  - Humans
KW  - Immunosuppressive Agents
KW  - Immunotherapy
KW  - International Agencies
KW  - Leflunomide
KW  - Lung Neoplasms
KW  - Maintenance Chemotherapy
KW  - Prognosis
KW  - Small Cell Lung Carcinoma
KW  - Survival Rate
KW  - Toll-Like Receptor 9
TI  - Immunotherapeutic maintenance treatment with toll-like receptor 9 agonist lefitolimod in patients with extensive-stage small-cell lung cancer: results from the exploratory, controlled, randomized, international phase II IMPULSE study.
TY  - research article
VL  - 29
ER  -